T2DM is a progressive disease with a complex pathophysiology.The kidney plays an
important role in glucose homeostasis, partly via the reabsorption of glucose from the glomerular
filtrate. Empagliflozinis an effective and highly selectivesodium glucose cotransporter-2 inhibitor
((SGLT2).This study aimedto assess metabolic effect of empagluazin in Libyan patients
withuncontrolled T2DM at National Diabetes Center, Tripoli, Libya in 2019.Prospective
interventional study, lasting for 24 weeks, included patients with uncontrolled T2DM, given
EMPA as an add on oral, once daily, anti-hyperglycemic treatment for patients with inclusion
criteria: age ≥18 years, high risk for cardiovascular diseases, patient with established CVD and
patient with satisfactory renal function e-GFR > 30 ml/min. Efficacy endpoints are change in
HbA1c, bodyweight,Bp, S. Na, fasting LDL-Cfrom baseline at 4 week, 12 weeks and at 24
weeks.Data analysis was done by SPSS program version 16.A total of 40 patients included in the
study, female were 70%, mean age was 62.05±9.77, (67.5%)were obese,mean body weight was
89.32±21.75, 67.5% were more than 10 years duration of T2DM, 67.5% were known
hypertensive, 72.5% were known CVD. There mean S. Na level were 140± 4.78, their HBA1c
were 10.3±1.83, 57.5% with previous history of urinary tract infection, starting Empagliflzin,
following with body weight,Bp, urine routine,S Cr,S.Naevery 2-week,4-week,12-week and 24-
week and HBA1c, fasting lipid at 12 and 24 week showna reduction in HBA1c by -3.72 to -
2.64.Reduction in body weight,especially in initial 4-week and obese casesby-14.4 to -9.78 kg,
systolic Bpshows drop especially in hypertensive cases (-10.05 to-4.08) with high S Na at
presentation (-4.56 to 1.8),initial mild train set increase in S Cr (0.03to0.19) followed by
reduction with moderate improvement in e-GFR (within same stage in CKD),no significant
changes in fasting lipid profile may be due to continue intake of statin. In

conclusion,Empagliflzin is a potent, anti-hyperglycemic drug with a good metabolic effect
showed reductions in glycated hemoglobin, marked reductions in the body weight and systolic
Bp, thus, supporting the use of empagliflozin as a mono-therapy or in addition to other glucoselowering agents especially in patients with T2DM and increased cardiovascular risk.

Keywords: Type 2 diabetes mellitus, sodium glucose co-transporter-2
inhibitor,Empagliflozin,cardiovascular disease, chronic kidney disease, Libya